The U.S. Food and Drug Administration is expected to issue a new and more stringent guidance regarding a potential Emergency Use Authorization (EUA) for a Covid–19 vaccine.

The U.S. Food and Drug Administration placed a hold on the Emergency Use Authorization for convalescent plasma as a potential treatment for Covid-19 over what was described as a lack of robust data supporting its use.